Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 93

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, Amos, Strandgren, Charlotte, Heldin, Angelos, Palomar-Siles, Mireia, Wiman, Klas G.·2024·Nature Reviews Clinical Oncology
DOI 10.1038/s41571-023-00842-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00842-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 136

  1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013). · DOI · Paper page
  2. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992). · DOI · Paper page
  3. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994). · DOI · Paper page
  4. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872 (2004). · DOI · Paper page
  5. Andrysik, Z. et al. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. Genome Res. 27, 1645–1657 (2017). · DOI
  6. Boutelle, A. M. & Attardi, L. D. p53 and tumor suppression: it takes a network. Trends Cell. Biol. 31, 298–310 (2021). · DOI · Paper page
  7. Levine, A. J. The many faces of p53: something for everyone. J. Mol. Cell. Biol. 11, 524–530 (2019). · DOI · Paper page
  8. Marchenko, N. D. & Moll, U. M. Mitochondrial death functions of p53. Mol. Cell. Oncol. 1, e955995 (2014). · DOI
  9. Diamond, B. et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood 141, 2359–2371 (2023).
  10. Xiong, S. et al. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Res. 82, 1926–1936 (2022). · DOI · Paper page
  11. Hoyos, D. et al. Fundamental immune–oncogenicity trade-offs define driver mutation fitness. Nature 606, 172–179 (2022). · DOI
  12. Klimovich, B. et al. p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene 41, 1011–1023 (2022). · DOI · Paper page
  13. Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA 102, 13550–13555 (2005). · DOI · Paper page
  14. Bouaoun, L. et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat. 37, 865–876 (2016). · DOI · Paper page
  15. Kratz, C. P. et al. Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an International Agency for Research on Cancer TP53 database analysis. JAMA Oncol. 7, 1800–1805 (2021). · DOI
  16. Pinto, E. M. et al. XAF1 as a modifier of p53 function and cancer susceptibility. Sci. Adv. 6, eaba3231 (2020). · DOI
  17. Leung, J. C. et al. Common activities and predictive gene signature identified for genetic hypomorphs of TP53. Proc. Natl Acad. Sci. USA 120, e2212940120 (2023). · DOI
  18. Zhou, W. et al. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Mol. Oncol. 3, 214–219 (2009). · DOI
  19. Lomakin, A. et al. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature 611, 594–602 (2022). · DOI · Paper page
  20. Galandiuk, S. et al. Field cancerization in the intestinal epithelium of patients with Crohn’s ileocolitis. Gastroenterology 142, 855–864.e8 (2012). · DOI
  21. Griffin, R. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 7, 3169–3179 (2023). · doi:10.1182/bloodadvances.2022009040
  22. Lundberg, P. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220–2228 (2014). · DOI · Paper page
  23. Maslah, N. et al. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 6, 2813–2823 (2022). · DOI · Paper page
  24. Rasche, L. et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat. Commun. 13, 4517 (2022). · DOI
  25. Gruber, M. et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature 570, 474–479 (2019). · DOI
  26. Hakkarainen, M. et al. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. Blood 141, 2853–2866 (2023).
  27. Li, C. et al. Whole exome and transcriptome sequencing reveal clonal evolution and exhibit immune-related features in metastatic colorectal tumors. Cell Death Discov. 7, 222 (2021). · DOI
  28. Karlsson, K. et al. Deterministic evolution and stringent selection during preneoplasia. Nature 618, 383–393 (2023). · DOI · Paper page
  29. Prokocimer, M., Molchadsky, A. & Rotter, V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood 130, 699–712 (2017). · DOI · Paper page
  30. Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Op. Genet. Dev. 10, 94–99 (2000). · DOI · Paper page
  31. Trinidad, A. G. et al. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol. Cell. 50, 805–817 (2013). · DOI
  32. Benor, G. et al. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features. Mol. Oncol. 14, 1640–1652 (2020). · DOI
  33. Tuval, A. et al. Pseudo-mutant p53 is a unique phenotype of DNMT3A-mutated pre-leukemia. Haematologica 107, 2548–2561 (2022). · DOI
  34. Haney, S. L. et al. Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma. PLoS Genet. 12, e1006334 (2016). · DOI
  35. Kodama, M. et al. Expression of mutant type-p53 products in H pylori-associated chronic gastritis. World J. Gastroenterol. 13, 1541–1546 (2007). · doi:10.3748/wjg.v13.i10.1541
  36. Wu, J., Wang, M., Li, X. & Sheng, Y. Conformation changes of p53 proteins in regulation of murine T lymphocyte proliferation. Cell Mol. Biol. Res. 39, 27–31 (1993).
  37. Milner, J. & Watson, J. V. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 5, 1683–1690 (1990).
  38. Sasaki, M., Nie, L. & Maki, C. G. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J. Biol. Chem. 282, 14626–14634 (2007). · DOI
  39. Hainaut, P. & Milner, J. A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53. Cancer Res. 53, 1739–1742 (1993).
  40. Hainaut, P. & Milner, J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53, 4469–4473 (1993).
  41. Furth, N. et al. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes. Dev. 29, 2325–2330 (2015). · DOI
  42. Zhang, W. & Deisseroth, A. B. Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells. Leuk. Lymphoma 14, 251–255 (1994). · DOI
  43. Zhu, Y. M., Bradbury, D. & Russell, N. Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br. J. Cancer 68, 851–855 (1993). · doi:10.1038/bjc.1993.444
  44. Rivlin, N. et al. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proc. Natl Acad. Sci. USA 111, 7006–7011 (2014). · DOI
  45. Blagosklonny, M. V., Toretsky, J. & Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11, 933–939 (1995).
  46. Tal, P. et al. Cancer therapeutic approach based on conformational stabilization of mutant P53 protein by small peptides. Oncotarget 7, 11817–11837 (2016). · DOI · Paper page
  47. Izquierdo, E. et al. Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. Blood 139, 3617–3629 (2022). · DOI
  48. Tan, X. et al. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J. Clin. Invest. 131, e137186 (2021). · DOI
  49. Maddalena, M. et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc. Natl Acad. Sci. USA 118, e2025631118 (2021). · DOI
  50. Arandkar, S. et al. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proc. Natl Acad. Sci. USA 115, 6410–6415 (2018). · DOI
  51. Cheteh, E. H. et al. Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov. 6, 42 (2020). · DOI
  52. Zhang, W. W. et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum. Gene Ther. 29, 160–179 (2018). · DOI · Paper page
  53. Li, Y. et al. Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. Int. J. Oral. Sci. 13, 38 (2021). · DOI
  54. Nemunaitis, J. et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin. Cancer Res. 15, 7719–7725 (2009). · DOI
  55. Bowman, K. E. R. et al. p53-Bad* fusion gene therapy induces apoptosis in vitro and reduces zebrafish tumor burden in hepatocellular carcinoma. Mol. Pharm. 20, 331–340 (2023). · DOI
  56. Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug. Discov. 22, 127–144 (2023). · DOI · Paper page
  57. Daver, N. G. et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 12, 2516–2529 (2022). · DOI
  58. Zhu, H. et al. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J. Hematol. Oncol. 15, 91 (2022). · DOI · Paper page
  59. Klein, A. M., de Queiroz, R. M., Venkatesh, D. & Prives, C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes. Dev. 35, 575–601 (2021). · DOI
  60. Feeley, K. P., Adams, C. M., Mitra, R. & Eischen, C. M. Mdm2 is required for survival and growth of p53-deficient cancer cells. Cancer Res. 77, 3823–3833 (2017). · DOI
  61. Adams, C. M. et al. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discov. 13, 1210–1229 (2023). · DOI
  62. Yee, K. et al. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1/1b study. Leuk. Res. 100, 106489 (2021). · DOI
  63. Konopleva, M. Y. et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 6, 4147–4156 (2022).
  64. Daver, N. G. et al. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood 141, 1265–1276 (2023). · DOI
  65. Napolitano, R. et al. Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Oncol. Rep. 44, 1561–1573 (2020).
  66. Ueda, K. et al. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell 39, 529–547.e7 (2021). · DOI
  67. Tessoulin, B. et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 124, 1626–1636 (2014). · DOI · Paper page
  68. Rabik, C. A. & Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33, 9–23 (2007). · DOI · Paper page
  69. Bewersdorf, J. P. et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk. Lymphoma 61, 2180–2190 (2020). · DOI
  70. Cluzeau, T. et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J. Clin. Oncol. 39, 1575–1583 (2021). · DOI · Paper page
  71. Mishra, A. et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J. Clin. Oncol. 40, 3985–3993 (2022). · DOI · Paper page
  72. Ghosh, A. et al. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J. Clin. Invest. 132, e148141 (2022). · DOI
  73. Park, H. et al. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 7, 100573 (2022). · DOI
  74. Garcia-Manero, G. et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 10, e272–e283 (2023). · DOI · Paper page
  75. DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791–803 (2020). · DOI · Paper page
  76. DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617–629 (2020). · DOI · Paper page
  77. Bao, W. et al. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 10, 301–307 (2011). · DOI
  78. Zhang, Q. et al. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 9, 439 (2018). · DOI · Paper page
  79. Khairul, I., Wang, Q. Q., Jiang, Y. H., Wang, C. & Naranmandura, H. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget 8, 23905–23926 (2017). · DOI · Paper page
  80. Chen, S. et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 39, 225–239.e8 (2021). · DOI · Paper page
  81. Dumbrava, E. E. et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 3003 (2022). · DOI
  82. Linde, L. & Kerem, B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 24, 552–563 (2008). · DOI · Paper page
  83. Howard, M., Frizzell, R. A. & Bedwell, D. M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467–469 (1996). · DOI · Paper page
  84. Burke, J. F. & Mogg, A. E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13, 6265–6272 (1985). · DOI · Paper page
  85. Floquet, C., Deforges, J., Rousset, J. P. & Bidou, L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res. 39, 3350–3362 (2011). · DOI · Paper page
  86. Floquet, C., Hatin, I., Rousset, J. P. & Bidou, L. Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genet. 8, e1002608 (2012). · DOI
  87. Zhang, M. et al. Synergistic rescue of nonsense mutant tumor suppressor p53 by combination treatment with aminoglycosides and Mdm2 inhibitors. Front. Oncol. 7, 323 (2018). · DOI
  88. Friesen, W. J. et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA 23, 567–577 (2017). · DOI
  89. Crawford, D. K., Alroy, I., Sharpe, N., Goddeeris, M. M. & Williams, G. ELX-02 generates protein via premature stop codon read-through without inducing native stop codon read-through proteins. J. Pharmacol. Exp. Ther. 374, 264–272 (2020). · doi:10.1124/jpet.120.265595
  90. Trzaska, C. et al. 2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. Nat. Commun. 11, 1509 (2020). · DOI
  91. Baradaran-Heravi, A. et al. Effect of small molecule eRF3 degraders on premature termination codon readthrough. Nucleic Acids Res. 49, 3692–3708 (2021). · DOI
  92. Palomar-Siles, M. et al. Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-fluorouridine. Cell Death Dis. 13, 997 (2022). · DOI
  93. Ivanov, A. et al. PABP enhances release factor recruitment and stop codon recognition during translation termination. Nucleic Acids Res. 44, 7766–7776 (2016). · DOI
  94. Kariv, R. et al. Resorting the function of the colorectal cancer gatekeeper adenomatous polyposis coli. Int. J. Cancer 146, 1064–1074 (2020). · DOI
  95. Wang, Z. et al. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death Differ. 30, 1033–1046 (2023). · DOI
  96. Milne, J. V. et al. Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation. Sci. Rep. 11, 4480 (2021). · DOI
  97. Guiley, K. Z. & Shokat, K. M. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discov. 13, 56–69 (2023). · DOI · Paper page
  98. Tang, Y. et al. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 39, 110622 (2022). · DOI · Paper page
  99. Friedman, D. N. et al. Clonal hematopoiesis in survivors of childhood cancer. Blood Adv. 7, 4102–4106 (2023). · DOI
  100. Calapre, L. et al. Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Sci. Rep. 13, 278 (2023). · DOI
  101. Ali, D. et al. Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br. J. Haematol. 174, 117–126 (2016). · DOI · Paper page
  102. Maiti, A. & Daver, N. G. Eprenetapopt in the post-transplant setting: mechanisms and future directions. J. Clin. Oncol. 40, 3994–3997 (2022). · DOI
  103. Ceder, S. et al. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Mol. Med. 13, e10852 (2021). · DOI · Paper page
  104. Ho, J. N. H. G. et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood 140, 1167–1181 (2022). · DOI
  105. Zhou, J. et al. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat. Immunol. 22, 460–470 (2021). · DOI · Paper page
  106. Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49–58 (2023). · DOI · Paper page
  107. Kotler, E. et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol. Cell. 71, 178–190.e8 (2018). · DOI · Paper page
  108. Lipkova, J. et al. Artificial intelligence for multimodal data integration in oncology. Cancer Cell 40, 1095–1110 (2022). · DOI · Paper page
  109. Joerger, A. C. & Fersht, A. R. The tumor suppressor p53: from structures to drug discovery. Cold. Spring Harb. Perspect. Biol. 2, a000919 (2010). · DOI · Paper page
  110. Soussi, T. & Wiman, K. G. TP53: an oncogene in disguise. Cell Death Differ. 22, 1239–1249 (2015). · DOI · Paper page
  111. Sabapathy, K. & Lane, D. P. Understanding p53 functions through p53 antibodies. J. Mol. Cell Biol. 11, 317–329 (2019). · DOI
  112. Light, N. et al. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat. Commun. 14, 77 (2023). · DOI
  113. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990). · DOI · Paper page
  114. Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018). · DOI · Paper page
  115. Colom, B. et al. Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature 598, 510–514 (2021). · DOI · Paper page
  116. Sperling, A. S. et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 140, 1753–1763 (2022). · DOI
  117. Lodé, L. et al. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica 103, e143–e146 (2018). · DOI · Paper page
  118. Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219–1226 (2020). · DOI · Paper page
  119. Marcellino, B. K. et al. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Adv. 4, 5735–5744 (2020). · DOI
  120. Raver-Shapira, N. et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell. 26, 731–743 (2007). · DOI · Paper page
  121. Vennin, C. et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat. Commun. 10, 3637 (2019). · DOI · Paper page
  122. Barak, Y., Juven, T., Haffner, R. & Oren, M. Mdm2 expression is induced by wild type-p53 activity. EMBO J. 12, 461–468 (1993). · DOI · Paper page
  123. Gu, J. et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277, 19251–19254 (2002). · DOI · Paper page
  124. Liu, X. et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41, 6034–6044 (2013). · DOI · Paper page
  125. Li, F. P. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48, 5358–5362 (1988).
  126. Chompret, A. et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J. Med. Genet. 38, 43–47 (2001). · DOI · Paper page
  127. Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100, 8424–8429 (2003). · DOI · Paper page
  128. Ben-Cohen, G. et al. TP53_PROF: a machine learning model to predict impact of missense mutations in TP53. Brief. Bioinform. 23, bbab524 (2022). · DOI
  129. Béroud, C. & Soussi, T. The UMD-p53 database: new mutations and analysis tools. Hum. Mutat. 21, 176–181 (2003). · DOI
  130. Carbonnier, V., Leroy, B., Rosenberg, S. & Soussi, T. Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. Sci. Rep. 10, 20368 (2020). · DOI
  131. Donehower, L. A. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 28, 1370–1384.e5 (2019). · DOI · Paper page
  132. Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471–480 (2020). · DOI · Paper page
  133. Sermeus, A. & Michiels, C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis. 2, e164 (2011). · DOI · Paper page
  134. Wang, Y., Pakunlu, R. I., Tsao, W., Pozharov, V. & Minko, T. Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis. Mol. Pharm. 1, 156–165 (2004). · DOI
  135. Saft, L. et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 99, 1041–1049 (2014). · DOI
  136. McGraw, K. L. et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica 101, e320–e323 (2016). · DOI

Cited by

See all 93

Metadata

Authors
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G.
ORCID
Venue
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2023-12-15
Volume
21
Issue
2
Pages
106-120
ISSN
  • 1759-4774
  • 1759-4782
DOI
10.1038/s41571-023-00842-2
Cited by
93
References
43
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological reactivation of p53 in the era of precision anticancer medicine. https://app.cochat.ai/papers/10.1038/s41571-023-00842-2
The paper
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024). Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00842-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.